CHICAGO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has signed a Laboratory Service Agreement (“LSA”) with Northwestern University (“Northwestern”). The LSA provides the Company access to Northwestern’s world class shared and core academic research facilities and resources, including its sophisticated imaging and instrumentation capabilities.
Access to these core facilities and laboratory equipment will play a critical role as BIOLIFE4D continues the development of its innovative technology and its core mission of being able to 3D bioprint a viable human heart for transplant. The Company will utilize the same resources that are pivotal to Northwestern’s research infrastructure that helps to facilitate groundbreaking science.
“We are honored to have the opportunity to utilize laboratory resources from the prestigious Northwestern University, where such groundbreaking scientific work has occurred. The importance of these resources to a pioneering biotech company really cannot be understated,” said Steven Morris, CEO, BIOLIFE4D. “This is a tremendous opportunity for our Company as we continue to develop our technology. Not only will it provide us access to world class labs, but it also enables us to utilize the most advanced, state-of-the-art equipment, staff, and facilities at these leading research centers. We want to change the world and are now better suited to do so.”
Through the LSA, BIOLIFE4D will have access to facilities at Northwestern’s Evanston and Chicago campuses, Argonne National Laboratory, and Northwestern Memorial Hospital, as well as the University of Chicago and University of Illinois at Chicago through Northwestern’s partnership in the Open Access Initiative.
To see how BIOLIFE4D’s process starts with a patient’s own cells and ends with a functional human heart ready for transplant, please watch this video.
To learn more about BIOLIFE4D and to express interest in investing please watch this video or visit https://biolife4d.com/invest/.
Securities are offered pursuant to a Regulation A+. Investors are encouraged to read the Offering Circular and exhibits and consult with their tax, legal, or financial professional prior to investing.
About BIOLIFE4D
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), Facebook, LinkedIn, and Instagram.
Forward Looking Statements
We caution you that, whether or not expressly stated, certain statements made in this news release that reflect management's expectations regarding future events and economic performance are forward-looking in nature and, accordingly, are subject to risks and uncertainties. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements.
Media Contact
Matthew Bretzius
FischTank Marketing and PR
biolife4d@fischtankpr.com